Altimmune (ALT) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Altimmune (ALT) has outperformed Oculis (OCS) over the past year, losing 32.3% versus a loss of 55.4%. Over five years, OCS leads with a -13.4% price change compared with -77.9% for ALT. Oculis is the larger company by market cap ($523.5 million vs $517.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | OCS |
|---|---|---|
| Share price | $2.66 | $8.50 |
| Market cap | $517.42M | $523.50M |
| 1-day change | -0.37% | -2.52% |
| YTD return | -26.32% | -57.44% |
| 1-year return | -32.32% | -55.40% |
| 5-year return | -77.85% | -13.44% |
| EPS (TTM) | $-0.75 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $34.48 |
| 52-week low | $2.56 | $8.30 |
| Distance from 52-week high | -58.70% | -75.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +543.23% | +329.29% |
| Average volume | 4.20M | 259.47K |
| Shares outstanding | 194.52M | 61.59M |
| Employees | 57 | 60 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALT has outperformed OCS by 23.1 percentage points over the past year.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Healthcare · Biotechnology · 57 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Healthcare · Biotechnology · 60 employees
ALT vs OCS FAQ
Which is bigger, Altimmune or Oculis?
Oculis (OCS) is larger, with a market capitalization of $523.50M compared with $517.42M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or OCS?
ALT returned -32.32% over the past 12 months, compared with -55.40% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and Oculis in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.